SUMMIT THERAPEUTICS INC (SMMT) Stock News
NASDAQ:SMMT - Nasdaq - US86627T1088 - Common Stock - Currency: USD
SMMT Latest News, Press Relases and Analysis
Treasury Yields Top 5%: These 20 Stocks Tanked In Just One Hour
The selloff came as investors repriced risk across equities amid fears of persistently higher rates, sparked by soft demand at the 20-year Treasury auction.
Bernstein Reaffirms Pfizer Rating After $6B Cancer Treatment Deal
Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on May 20, following the company’s recently disclosed $6 billion licensing deal with 3SBio Inc. to develop and market the cancer treatment SSGJ-707. While a notable venture at face value, the deal has raised questions about Pfizer’s continued collaboration with […]
1 Warren Buffett Stock That Could Go Parabolic in 2025 and Beyond
SiriusXM is one of the worst-performing Warren Buffett stocks in recent years. There are some extremely attractive stocks in Berkshire Hathaway's (NYSE: BRK.A)(NYSE: BRK.B) closely followed stock portfolio right now. For example, Amazon.com (NASDAQ: AMZN) is one of my favorite Buffett stocks, but with a roughly $2 trillion valuation, it isn't likely to produce massive gains in a short time frame.
Can Summit Therapeutics Stock Double Your Money?
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil
SMMT's first-quarter earnings outpace estimates. The company also provides updates on its pipeline.
This Soaring Stock Just Delivered More Good News. Time to Buy?
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech
PFE in-licenses global rights, ex-China, to SSGJ-707, from Chinese biotech, 3SBio for an upfront payment of $1.25 billion.
Pfizer Strikes up to $6.05 Billion Licensing Deal for 3SBio's Cancer Drug Candidate
Pfizer (PFE) secured exclusive global rights, excluding China, to biopharmaceutical firm 3SBio's can
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money
Applied Digital has a huge growth opportunity with the explosion in demand for data centers. IonQ is a pioneer in the fast-growing quantum computing market. Summit Therapeutics has a promising cancer immunotherapy in late-stage development.
3 Magnificent Stocks That Are Passive Income Machines
Abbott Laboratories is a dividend stock you can buy and (almost) forget about. AbbVie has proved its resilience by becoming stronger after losing patent exclusivity for its blockbuster drug Humira. Johnson & Johnson is a seasoned dividend payer for all seasons.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain
We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology […]
Can Summit Therapeutics Stock Double Your Money?
The stock's high price tag could be a problem for investors looking for a big return. Summit Therapeutics (NASDAQ: SMMT) has more than just a potential blockbuster cancer drug in its portfolio. This has investors excited that Summit may be one of the next big healthcare companies in the world.
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know
The consensus price target hints at a 33.4% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How the stock market made back all its losses after Trump escalated the trade war
It felt much longer, but the U.S. stock market needed just a few weeks to roar all the way back to where it was on President Donald Trump's “Liberation Day.” Within just four days, the S&P 500 fell about 12%, and the Dow Jones Industrial Average lost nearly 4,600 points, or about 11%. This past Friday, though, the S&P 500 rallied 1.5% for a ninth straight gain and pulled back to where it was on April 2.
Berkshire investors anticipate new era as Buffett hands over baton
OMAHA, Nebraska (Reuters) -Berkshire Hathaway shareholders mourning the departure of legendary investor Warren Buffett anticipate the conglomerate he built over 60 years will retain its long-term focus and culture but worry about the loss of Buffett's vision and star power. Following Buffett's surprise announcement on Saturday that he would step down as chief executive by the end of the year, Berkshire shareholders and fans said the Omaha, Nebraska-based company will remain in good hands once Vice Chairman Greg Abel takes the top job. But they said it remains unclear how the $1.16 trillion conglomerate, which has 189 operating businesses, $264 billion of stocks and $348 billion of cash, will fare after the man so intertwined with it leaves the stage.
Why DexCom Inc. (DXCM) Soared Last Week
We recently published a list of These 10 Firms Soared Last Week, Here’s Why. In this article, we are going to take a look at where DexCom Inc. (NASDAQ:DXCM) stands against other firms that soared last week. The past trading week saw a more calm, generally optimistic, market environment amid the temporary pause in tit-for-tat […]
Why Summit Therapeutics Inc. (SMMT) Soared Last Week
We recently published a list of These 10 Firms Soared Last Week, Here’s Why. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other firms that soared last week. The past trading week saw a more calm, generally optimistic, market environment amid the temporary pause in tit-for-tat […]
Buffett passes the torch — here’s what Berkshire loyalists should know, from a longtime insider
Buffett’s CEO successor Greg Abel may bring a change in style, greater collaboration.
Meet This Monster Dividend Stock That Continues to Crush the Market in 2025
British American Tobacco has a 7% dividend yield. Price hikes and growth in smokeless nicotine products should drive earnings growth in the years ahead. The financials indicate that British American Tobacco can keep growing its dividend per share in the future.
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.
Akeso survival data for ivonescimab misses expectations, STAT says
While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, Jonathan Wosen of STAT reports. In its submission to regulators, Akeso included data on patient survival, disclosing that an interim analysis following 157 patient deaths found that participants on ivonescimab had a roughly 22% reduced risk of death, with a hazard ratio of 0.784, a company spokesperson
4 Pipeline Stocks to Buy With $1,000 and Hold Forever
Pipeline companies remain well positioned despite the current disruption in the energy markets. At the same time, demand for natural gas is growing. This is coming from the increased power consumption stemming from artificial intelligence (AI), as well as from export demand from Mexico and for LNG (liquified natural gas) to Asia and Europe.
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic
The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials.